Figure 1.

Occurrence and crude incidence rates of haematological malignancy per Nordic country in TNFi-treated and bDMARD-naïve patients with psoriatic arthritis and matched general population comparators, and for patients with PsA overall compared with matched general population comparators. General population TNFi was matched by sex, year of birth and calendar period to the TNFi-exposed PsA patients. And for SE also by area of residence. General population PsA was matched by sex, year of birth and calendar period to all PsA patients. And in SE also by area of residence. Data from FI, NO, ICE are presented together due to few cancer events per country. bDMARDs, biological disease-modifying anti-rheumatic drugs; CRR, clinical rheumatology register; DK, Denmark; event, first ever haematological cancer, that is, previous other malignancies are allowed; FI, Finland; ICE, Iceland; NO, Norway; NPR, national patient register (only available in Sweden and Denmark); PsA, psoriatic arthritis; SE, Sweden; TNFi, tumour necrosis factor inhibitor.